Dragon Pharma, Europe
YK11
Oral · 10 mg/tab · 100 tabs
$135.00
Compound ID
YK-11
Dosage
5–15 mg/day
Concentration
10 mg/tablet
Form
100 Tablets × 10 mg
Half-life
Approximately 6–10 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma YK-11 10mg — Myostatin-Modulating SARM for Extreme Muscle Density & Genetic Limit Breakthrough
Dragon Pharma YK-11 10mg occupies a unique position at the frontier of muscle-building pharmacology, functioning simultaneously as a selective androgen receptor modulator and a potent myostatin inhibitor. Myostatin, a growth differentiation factor encoded by the MSTN gene, acts as the body's primary biological constraint on skeletal muscle hypertrophy and hyperplasia. By antagonizing this regulatory protein, YK-11 effectively dismantles the physiological ceiling that limits muscularity in genetically typical individuals, enabling gains in density, hardness, and fiber quality that transcend conventional anabolic boundaries. Dragon Pharma's precisely manufactured 10mg tablets undergo rigorous independent verification, delivering a research-grade compound for advanced athletes who have exhausted standard hypertrophy pathways and demand a mechanism capable of unlocking unprecedented tissue development.
What is Dragon Pharma YK-11?
YK-11 is a steroidal SARM derived from dihydrotestosterone (DHT) that exhibits a unique dual pharmacological profile. In addition to binding androgen receptors with high affinity in skeletal muscle and bone, it functions as a partial agonist of the androgen receptor while simultaneously upregulating follistatin expression—a potent myostatin-binding protein that neutralizes myostatin's inhibitory signaling. This dual action not only stimulates traditional AR-mediated anabolism but also removes the endogenous brake on muscle growth, permitting both hypertrophy (increase in fiber size) and hyperplasia (increase in fiber number). Unlike conventional SARMs that merely activate anabolic pathways, YK-11 genetically reprograms the muscle's growth potential, making it one of the most aggressively potent compounds in the performance-enhancement landscape. Its steroidal backbone also confers greater lipophilicity, enhancing cellular uptake but introducing hepatic metabolism considerations absent in non-steroidal alternatives.
Key Benefits / Effects
- Exceptional Muscle Density & Hardness: Gains are characterized by a rock-like, grainy quality distinct from the water-retentive bulk of aromatizing compounds, producing a visually striking, carved appearance even at rest.
- Myostatin Pathway Inhibition: By elevating follistatin and suppressing myostatin signaling, YK-11 removes the primary biological constraint on muscle size, enabling growth beyond typical genetic thresholds.
- Unique Three-Dimensional Fullness: Hyperplasia-driven increases in muscle fiber count create a round, volumetric "3D" effect that pushes muscle bellies against the skin with pronounced separation and roundness.
- Explosive Strength Acceleration: Rapid improvements in contractile tissue density translate directly into personal record-breaking lifts and increased force output within the first few weeks of administration.
- Enhanced Vascular Definition: The dry, dense tissue environment and reduced subcutaneous fluid promote striking venous prominence and muscle striation visibility.
- Recomposition Potential: Potent anabolic signaling elevates basal metabolic rate and nutrient partitioning efficiency, supporting simultaneous lean mass accretion and adipose reduction when combined with structured nutrition.
How Dragon Pharma YK-11 Works
YK-11 initiates its effects through high-affinity binding to androgen receptors in skeletal myocytes, activating the same genomic transcription pathways responsible for muscle protein synthesis, satellite cell activation, and myonuclear domain expansion. However, its distinguishing mechanism involves the induction of follistatin—a secreted glycoprotein that binds and inactivates myostatin before it can interact with activin type II receptors on muscle membranes. Under normal physiology, myostatin restricts muscle growth by inhibiting satellite cell proliferation and promoting protein catabolism. By neutralizing this signal, YK-11 permits unchecked myogenic differentiation and fiber recruitment. The compound's DHT-derived structure also contributes to its strong androgenic character, enhancing neuromuscular efficiency and contractile force generation. The net result is a compound that not only stimulates growth but actively dismantles the biological limits preventing it, creating a physiological environment conducive to muscularity typically observed only in myostatin-deficient genetic variants.
Usage Information
Dragon Pharma YK-11 is supplied as 10mg oral tablets with a relatively short pharmacokinetic half-life of approximately 6–8 hours, necessitating split-dose administration for stable plasma concentrations. Due to its potent suppressive nature and advanced mechanism, YK-11 is not recommended for novice users. Intermediate practitioners typically employ 10mg daily, divided into two 5mg doses spaced roughly 8 hours apart. Advanced users may escalate to 15–20mg daily, split into two or three administrations, though doses exceeding 20mg substantially increase hepatotoxic and suppressive risks with diminishing hypertrophic returns. Administration with meals containing dietary fats enhances lipophilic absorption. Cycle duration should be strictly limited to 8 weeks due to liver strain and profound hypothalamic-pituitary-gonadal axis suppression. A comprehensive Post-Cycle Therapy protocol is absolutely mandatory, and a testosterone base is strongly recommended to prevent severe low-androgen symptoms during the cycle.
Quality & Manufacturing
Dragon Pharma implements stringent quality-assurance frameworks across all production lines, with independent third-party laboratories verifying each batch for active ingredient identity, concentration accuracy, and contaminant absence. The 10mg YK-11 tablets are manufactured under controlled conditions to ensure uniform distribution of this potent steroidal SARM within each dose unit. Given the compound's advanced nature and the precision required for safe, effective myostatin modulation, dosing consistency is paramount. Underdosed products would fail to achieve meaningful follistatin upregulation, while overdosed or impure alternatives could expose users to unpredictable androgenic and hepatotoxic burdens. Dragon Pharma's analytical rigor ensures that every tablet delivers the exact pharmacological payload required for advanced athletes to explore their genetic muscle-building potential with confidence and predictability.
Possible Side Effects / Safety Information
- Profound Testosterone Suppression: YK-11 exerts severe negative feedback on the hypothalamic-pituitary-gonadal axis, often producing complete shutdown of endogenous testosterone synthesis. A testosterone base and aggressive PCT with Clomiphene and Tamoxifen are non-negotiable.
- Hepatic Stress: As a steroidal compound with structural similarity to DHT, YK-11 places measurable strain on hepatic enzyme systems. Cycle length must not exceed 8 weeks, and dedicated liver support with TUDCA and N-acetylcysteine is essential.
- Androgenic Manifestations: Users may experience acne vulgaris, accelerated androgenic alopecia in genetically predisposed individuals, and increased terminal hair growth due to the compound's strong androgen receptor affinity.
- Dyslipidemia: YK-11 can significantly depress HDL cholesterol while elevating LDL cholesterol, necessitating cardiovascular monitoring, omega-3 supplementation, and dietary intervention.
- Tendon and Ligament Risk: The rapid, dense muscle growth may outpace connective tissue adaptation, increasing susceptibility to strains or tears. Conservative loading, thorough warm-ups, and avoidance of maximal attempts are prudent precautions.
- Absence of Estrogenic Activity: YK-11 does not aromatize to estrogen, eliminating gynecomastia, water retention, and blood pressure elevation from estrogenic sources.
Why Choose Dragon Pharma YK-11?
Myostatin inhibition represents one of the most advanced frontiers in physique enhancement, and product integrity is absolutely critical when manipulating such powerful biological pathways. Dragon Pharma's commitment to third-party analytical verification ensures that each 10mg tablet contains the precise YK-11 concentration required for meaningful follistatin induction and myostatin suppression. In a marketplace rife with mislabeled research chemicals and underdosed alternatives, this level of quality control protects advanced users from the frustration of ineffective protocols and the dangers of uncharacterized contaminants. For athletes who have plateaued on conventional anabolics and SARMs, Dragon Pharma YK-11 offers a scientifically distinct mechanism capable of breaking through genetic barriers to achieve muscle density and hardness previously considered unattainable.
Product FAQ
Questions, answered
While conventional SARMs activate androgen receptors to stimulate protein synthesis, YK-11 adds a second, distinct mechanism: myostatin inhibition through follistatin upregulation. This dual action not only promotes hypertrophy but also permits hyperplasia—increasing the actual number of muscle fibers rather than merely expanding existing ones. The result is a qualitatively different type of growth characterized by extreme density, hardness, and a three-dimensional fullness that standard SARMs cannot replicate.
No. YK-11 is explicitly an advanced compound reserved for experienced users with multiple prior SARM or anabolic steroid cycles. Its profound suppressive nature, hepatotoxic potential, and requirement for split-dose administration, testosterone bases, and comprehensive PCT make it inappropriate for novices. Individuals new to performance enhancement should begin with milder, non-steroidal SARMs and develop a thorough understanding of their hormonal response before considering YK-11.
YK-11's potent suppression rapidly depletes endogenous testosterone, leading to low-estrogen symptoms including lethargy, joint pain, diminished libido, and mood disturbances. A testosterone base—typically 200–400mg weekly of Testosterone Enanthate or Cypionate—maintains physiological androgen levels, preventing these debilitating symptoms while allowing YK-11 to exert its unique myostatin-inhibiting effects. An aromatase inhibitor should be kept available to manage estrogen from the testosterone base.
Given its steroidal structure and hepatic metabolism, YK-11 requires dedicated organ protection. TUDCA at 500mg daily and N-acetylcysteine (NAC) at 1200mg daily represent standard protective protocols. Avoidance of alcohol, acetaminophen, and other hepatotoxic agents is mandatory. Pre-cycle and mid-cycle liver enzyme panels (ALT, AST, GGT) should be conducted to monitor hepatic status throughout the 8-week cycle.
Due to the 6–8 hour half-life, split dosing is essential. Intermediate users should administer 5mg every 8 hours (total 10mg daily), while advanced users may use 5mg three times daily (total 15mg) or adjust to 20mg split across two or three doses. Taking doses with meals containing healthy fats improves absorption of this lipophilic steroidal compound. Consistent timing each day maintains stable plasma concentrations and maximizes myostatin suppression.
PCT must be aggressive and comprehensive due to the depth of suppression. A standard protocol includes Clomiphene Citrate at 50/50/25/25mg and Tamoxifen Citrate at 40/20/20/20mg over four weeks. For users who ran a testosterone base, PCT timing should account for the ester clearance of the injectable testosterone. HCG at 500–1000IU every other day for the two weeks preceding SERM initiation can prime testicular responsiveness. Blood work confirming recovered LH, FSH, and total testosterone should precede any subsequent cycle.
No. YK-11 does not aromatize to estrogen and possesses no progestogenic activity, eliminating the risk of estrogen-mediated gynecomastia, subcutaneous water retention, or blood pressure elevation from fluid accumulation. The physique changes produced are characteristically dry, hard, and dense. However, users running a testosterone base must still manage estrogen from the exogenous testosterone via aromatase inhibitors if necessary.
For maximum mass accretion, stack with LGD-4033 and MK-677 to combine volumetric growth, myostatin inhibition, and growth hormone-mediated recovery. For pre-contest hardness, combine with S-23 and a testosterone propionate base to achieve extreme density and dryness. YK-11 also pairs well with Epitalon for experimental gene-expression optimization. Never stack YK-11 with other hepatotoxic orals without careful risk assessment and liver monitoring.
Users typically report noticeable increases in muscle hardness and training aggression within the first 10–14 days. Visible density changes and vascular enhancement consolidate by weeks 3–4, with maximal results appearing in the final weeks of the 8-week cycle. Because myostatin inhibition works through genetic and cellular adaptation rather than acute fluid shifts, the gains are slower to initiate but substantially more permanent and qualitatively distinct than water-weight bulk.
Yes. The rapid increase in contractile force and muscle density can outpace collagen synthesis and connective tissue remodeling, creating a dangerous strength-to-tendon-capacity mismatch. Users should avoid maximal single-repetition attempts, prioritize thorough dynamic warm-ups, and consider collagen supplementation with vitamin C to support connective tissue health. Listening to joint signals and avoiding sudden load spikes is essential for injury prevention.
